Dr Cliff Rowe
BSc (Hons), PhD.
Director and Principal Consultant.
Experienced in leading R&D, MedTech & BioTech Strategy, Team Leadership, Pharmacology and Toxicology, Medical Device Biocompatibility, Drug Delivery, Cell and Gene Therapy.
Discover how MedRow Scientific can assist you with your Life Sciences or Medical Device Development Projects.
About
Dr Cliff Rowe, Director and Prinicpal Consultant, launched MedRow Scientific in 2025 to help Life Science and Medical Device companies navigate their Research and Development challenges.
Cliff graduated with a first-class BSc (Hons) in Pharmacology from the University of Liverpool in 2000 before taking a MRC/Smithkline Beecham CASE PhD Studentship at the University of Aberdeen investigating the molecular mechanisms underlying the induction of drug metabolising Cytochrome P450 enzymes. Since completion of his PhD in 2004 Cliff has built a wealth of experience in R&D having worked for more than 20 years on diverse Life Sciences and Medical Device development projects in academia and industry.
Research specialities include:
Hepatocytes and cell line models for hepatotoxicity testing
Human liver development & stem cell differentiation
Development of multi-cell type New Approach Methodologies
Drug-delivery technologies
A publication list is provided for more information.
After postdoctoral projects at the Universities of Aberdeen, Liverpool and Manchester he moved to work in industry from 2013. As Principal Scientist at CN Bio Innovations he managed internal research activities developing Liver on Chip technology and worked across several internationally partnered projects.
In April 2015 Cliff joined OxSonics Therapeutics, working on a novel ultrasound mediated drug delivery technology desinged to enhance the dose and distribution of biologics within solid tumours. As part of the Leadership Team (Development Director) he built and led the in-house biology and chemistry teams, managed internal proof of concept data generation, GMP manufacturing scale-up activities and GLP, ISO 10993 compliant preclinical safety assessments.
A committed life-long learner, Cliff maintains a strong scientific interest in Toxicology, Proteomics, Transcriptomics, Bioinformatics, New Approach Methodologies, Biosafety and Cell and Gene therapies. He is a current member of the Royal Society of Biology and The International Society for Cell & Gene Therapy.